Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing etripamil, a nasal spray therapy for cardiovascular conditions. The company is preparing for potential U.S. commercialization of CARDAMYST for paroxysmal supraventricular tachycardia (PSVT) while also evaluating additional indications such as atrial fibrillation with rapid ventricular rate.

8.01

7.96

— Milestone Pharmaceuticals Inc.
%
Lead product candidate90% Etripamil-based nasal spray therapy being developed and prepared for commercialization.
Pipeline expansion5% Additional indications and future cardiovascular uses for etripamil.
Partnering and licensing5% Potential milestone-based license revenue and regional commercialization rights.

Milestone does not yet sell approved products, so its current 'customers' are mainly regulators, clinical trial sites,...

  • Regulators and clinical development ecosystemprimary

    FDA, CROs, CMOs, and trial sites that enable development, review, and approval of etripamil.

  • U.S. PSVT patients and prescribersprimary

    Cardiology and emergency-care prescribers treating PSVT patients with a potential self-administered nasal therapy.

  • Payers and pharmacy access stakeholderssecondary

    Insurers, PBMs, and pharmacy channels that will influence reimbursement and adoption after launch.

  • International licensing partnerssecondary

    Companies that may commercialize or develop etripamil outside the United States.

Milestone is headquartered in the United States and plans to commercialize etripamil directly in the U.S. if approved...

  • •United States is the planned first commercial market for CARDAMYST
  • •U.S. operations drive clinical, regulatory, and launch preparation spending
  • •Outside the U.S., commercialization may rely on partners or collaborations
  • •Greater China is specifically mentioned as a region outside the current rights scope
  • •Global supplier and trade exposure creates indirect international risk

Milestone's strategy is centered on completing development and regulatory remediation for etripamil, then launching...

01
Obtain FDA approval for CARDAMYSTshort-term

Approval is the key gating event for first product revenue and commercial entry.

02
Prepare a U.S. direct sales launchshort-term

A direct commercial model is intended to capture value if approval is secured.

03
Expand etripamil into additional indicationsmedium-term

A broader label could increase the product's addressable market and lifecycle value.

04
Pursue partnering and licensing opportunitiesmedium-term

Partnerships can extend geographic reach and reduce capital needs outside the U.S.

Milestone is highly dependent on a single asset, etripamil, so regulatory setbacks or clinical failure would materially...

critical

Regulatory approval failure or delay for etripamil

The company has only one product candidate and revenue depends on FDA approval.

Scope
CARDAMYST / PSVT launch
Materiality
high
high

Capital shortfall and dilution

The company continues to incur operating losses and has limited cash relative to launch and development needs.

Scope
R&D and commercialization funding
Materiality
high
high

Clinical development uncertainty

Trial outcomes, timelines, and costs can differ materially from expectations.

Scope
PSVT, AFib-RVR, and future indications
Materiality
high
medium

Commercial launch execution risk

A direct U.S. launch requires infrastructure, personnel, and payer access capabilities.

Scope
U.S. commercialization
Materiality
medium
medium

Trade and supply-chain disruption

The company relies on third-party suppliers in several countries outside the U.S.

Scope
Outsourced development and manufacturing network
Materiality
medium
Clinical trial accrual estimates
Can shift expenses between quarters and change reported operating loss
Share-based compensation valuation
Non-cash expense can materially affect reported losses
Milestone-based license revenue
Revenue may be lumpy and unpredictable
Launch and commercialization cost timing
Quarterly operating expense volatility

KalVista Pharmaceuticals, Inc.

Pharmaceutical Preparations

MILESTONE SCIENTIFIC INC.

MLSS · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

TENAX THERAPEUTICS, INC.

TENX · Pharmaceutical Preparations

CYTOKINETICS INC

CYTK · Pharmaceutical Preparations

Karyopharm Therapeutics Inc.

KPTI · Pharmaceutical Preparations

: 28/04/2026